On July 30, Keros Therapeutics, Inc. (NASDAQ:KROS) triggered a $20 million development milestone payment from its global partner Takeda Pharmaceutical Company Limited (NYSE:TAK). The payout followed the first patient dosed in the Phase 3 ELRiSE MDS clinical trial, evaluating elritercept against epoetin alfa for anemia caused by low-to-intermediate-risk myelodysplastic syndromes. Under their January 2025 global licensing deal, Keros had already received a $200 million upfront cash payment in February 2025 and remains eligible for over $1.1 billion in total milestones plus tiered royalties.
Keros plans to distribute 25% of the net cash proceeds from this $20 million milestone directly to its stockholders. Comparing Keros Therapeutics, Inc. (NASDAQ:KROS)' Q2 2026 results against Takeda Pharmaceutical Company Limited (NYSE:TAK)'s Q1 FY2026 performance highlights the stark difference between a clinical-stage biotech and a global pharmaceutical powerhouse. In Q2 2026, Keros Therapeutics, Inc. reported $0 in total revenue, down from $18.2 million in Q2 2025, and a net loss of $28.7 million ($1.45 per share).
However, its loss narrowed from $30.7 million a year ago as research and development expenses dropped sharply to $22.3 million from $43.5 million. This cost reduction stems from transitioning elritercept's development expenses to Takeda and completing a 2025 corporate restructuring. Supported by $257.6 million in cash and equivalents at quarter-end, Keros boasts a clean cash runway into the first half of 2028.
Takeda Pharmaceutical Company Limited, by contrast, operates at immense commercial scale. For Q1 FY2026, Takeda reported revenue of JPY 1.22 trillion (~$7.5 billion), up 10.2% on actual exchange rates despite a 0.5% slip at constant currency due to mature product headwinds. Core EPS reached JPY 154 billion, and the company reaffirmed its full-year outlook, including expected adjusted free cash flow of JPY 650 billion to JPY 750 billion.
Financially, TAK is clearly doing better in terms of top-line revenue, commercial cash generation, and operating profit. However, KROS is executing exceptionally well for a clinical-stage firm by offsetting R&D burn through Takeda's balance sheet, maintaining zero debt burden, and returning capital to shareholders. The bull case for Keros centers on non-dilutive capital and major pipeline upside.
Successful Phase 3 trials for elritercept could unlock over $1.1 billion in future milestone payments and high-margin royalties, while its cash cushion covers operations through 2028. The bear case stems from its reliance on a single lead clinical candidate and total dependence on Takeda for commercial execution outside China. For Takeda, the bull case rests on its steady cash flow, high-margin core portfolio (like Entyvio), and low-risk expansion via partnered late-stage assets.
Extract — continue reading at the source.
